About Deciphera
Deciphera is a company based in Waltham (United States) founded in 2003 was acquired by ONO PHARMACEUTICAL in April 2024. Deciphera has raised $172.9 million across 3 funding rounds from investors including Lilly, New Leaf Venture Partners and ONO PHARMACEUTICAL. The company has 394 employees. Deciphera offers products and services including Ripretinib, Vimseltinib, DCC-3116, DCC-3084, and DCC-3009. Deciphera operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Waltham, United States
- Employees 394
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website deciphera.com
- Social LinkedIn X
- Acquired by ONO PHARMACEUTICAL (Apr 2024)
- Legal Name Deciphera Pharmaceuticals, Llc
- Annual Revenue$163.36 M (USD)22as on Dec 31, 2023
- Net Profit-$194.94 M (USD)-9as on Dec 31, 2023
- EBITDA-$210.96 M (USD)-15as on Dec 31, 2023
- Total Equity Funding$172.9M (USD)
in 3 rounds
- Latest Funding Round$52.3M (USD), Series C
Jun 2017
- InvestorsLilly
& 6 more
- Employee Count394
- Acquired byONO PHARMACEUTICAL
(Apr 2024)
Products & Services of Deciphera
Deciphera offers a comprehensive portfolio of products and services, including Ripretinib, Vimseltinib, DCC-3116, DCC-3084, and DCC-3009.
Kinase inhibitor targeting cancer growth and resistance
Kinase inhibitor for specific cancer treatments
Experimental kinase inhibitor in preclinical stages
Kinase inhibitor for oncology applications
Preclinical kinase inhibitor for cancer therapy
Funding Insights of Deciphera
Deciphera has successfully raised a total of $172.9M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $52.3 million completed in June 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $172.9M
- Total Rounds 3
- Last Round Series C — $52.3M
- First Round $30M
(Apr 2014)
- Investors Count 6
All 3 funding rounds of Deciphera with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2017 | $52.3M | Series C | – | Viking Global Investors, Redmile Group | |
| Jul 2016 | $90.6M | Series B | – | New Leaf Venture Partners | |
| Apr 2014 | $30M | Series A | – | – |
7 investors in total: 7 institutional.
Investors in Deciphera
Deciphera has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, New Leaf Venture Partners and ONO PHARMACEUTICAL.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private investment firm focused on multiple sectors | – | vikingglobal.com | Greenwich, United States | |
Stage-agnostic investments in US life sciences are managed. | 2005 | nlvpartners.com | New York, United States | |
Venture capital fund focused on early-stage healthcare startups | – | svhealthinvestors.com | Boston, United States | |
Operates as an employee-owned hedge fund focused on long/short equity strategies. | 2007 | redmilegroup.com | San Francisco, United States | |
Manages hedge funds with long/short equity and real estate strategies for investors. | 2004 | spherafund.com | Tel Aviv, Israel | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | lilly.com | United States | |
R&D company focused on manufacturing of drugs for multiple therapeutic areas | 1947 | ono-pharma.com | Osaka, Japan |
Investor details for Deciphera
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Deciphera
169 people are tracked at Deciphera (111 in leadership, 6 in board & advisors, 52 in team); the tracked headcount is 394.
| Name | Role | Group |
|---|---|---|
Anna Papinska | Associate Director, Clinical Pharmacology | Leadership |
Sutapa Mukhopadhyay | Senior Director, Pharmacovigilance Operations | Leadership |
Melissa P. | Director, Market Access Strategy And Marketing | Leadership |
Joaninha Darosa | Director, Contracts | Leadership |
Pamela Munroe | Director, Head Of Regulatory Operations And Project Management | Leadership |
Adam Terreri | Director, US Brand Lead, Romvimza | Leadership |
Stephanie E. Bryant | Senior Director, Patient Advocacy And Engagement | Leadership |
Kelley Dealhoy | SVP & Chief Business Officer | Leadership |
Christopher Tait | Senior Director Biostatistics | Leadership |
Mona Patel | Director | Leadership |
Margarida Duarte | SVP & Head of International | Leadership |
Joseph Shibley | Associate Director | Leadership |
Patrick Boulay | Associate Director, Quality Systems And Compliance | Leadership |
Kelly Barfield | Senior Director, Field Access | Leadership |
Lisa Kiniklis | Senior Director, Market Access Operations, Contracts & Pricing | Leadership |
Tom B. | Vice President Of Commercial Insights & Operations | Leadership |
Mike Delorey | Senior Director, I&t Business Relationship Management - Commercial | G&a | International | Leadership |
Ashley Higgins | Associate Director, Pharmacovigilance Scientist | Leadership |
Priya Jain | Vp, Head Of Pharmacovigilance | Leadership |
Charles Psoinos M.D. | Senior Medical Director, Clinical Development | Leadership |
149 more people are available in the full profile.
Complete people profiles for Deciphera
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Deciphera
5 dated milestones of Deciphera across 21 years, from founding to its latest funding, stage changes and deals.
- Founded Deciphera is founded.
- Funding First funding round of $30.0M.
- Funding Latest funding round, Series C, of $52.3M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by ONO PHARMACEUTICAL.
Competitors of Deciphera
Deciphera operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| adacap.com | 2002 | Saint Genis Pouilly, France | $56.13M | – | Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | |
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| blueprintmedicines.com | 2008 | Cambridge, United States | $115M | 201 | Selective kinase inhibitors are developed for genomically defined cancers. | |
| syndax.com | 2005 | Waltham, United States | $198.29M | 107 | Targeted therapies for cancer treatment are developed. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. |
Detailed competitors of Deciphera
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Deciphera
The website of Deciphera (deciphera.com) receives about 12.2K visits a month and ranks #2,044,202 among all websites worldwide, #2,782 in Biotechnology and Pharmaceuticals.
- Monthly visits12.2K
▲ 22.3% vs previous month
- Unique visitors4.4K
per month
- Global rank#2,044,202
among all websites
- Category rank#2,782
Health · Biotechnology and Pharmaceuticals
- Bounce rate35%
- Pages per visit2.3
- Average visit17 sec
- DevicesDesktop 38% · Mobile 62%
Websites whose visitors overlap most with Deciphera. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| santhera.com | 100% | 12.6K | #3,177,070 | View details | |
| sucampo.com | 100% | – | – | View details | |
| nulifepharma.com | 100% | – | #3,772,642 | View details | |
| quarkpharma.com | 100% | – | – | View details | |
| auspexpharma.com | 99% | – | – | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 12 similar websites and full traffic analytics for Deciphera
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Deciphera
Complete news archive for Deciphera
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Deciphera
10 companies that operate in the same segment as Deciphera (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Deciphera
Deciphera was founded in 2003 and raised its 1st funding round 11 years after it was founded.
Deciphera is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Deciphera is a funded company, having raised a total of $172.9M across 3 funding rounds to date. The company's 1st funding round was a Series A of $30M, raised on Apr 2014.
Deciphera has 394 employees.
Annual revenue of Deciphera is $163.36M as on Dec 31, 2023.
Deciphera was founded in 2003 in Waltham, United States, within the biotechnology sector. A proprietary switch-control kinase inhibitor platform is utilized by the company, combined with expertise in kinase biology, to advance a portfolio of cancer therapies. Focus is placed on type 2 kinase inhibitors aimed at addressing unmet needs in oncology. Operations center on research and development for novel medicinal products in the United States.
Deciphera's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Deciphera offers Ripretinib, Vimseltinib, DCC-3116, DCC-3084, and DCC-3009.
Deciphera has 7 investors. Key investors include Lilly, New Leaf Venture Partners, ONO PHARMACEUTICAL, Viking Global Investors, and Redmile Group.
Deciphera operates through Deciphera Pharmaceuticals, Llc.
Yes. Deciphera was acquired by ONO PHARMACEUTICAL in April 2024.